Sohn J H, Kaplan H J, Suk H J, Bora P S, Bora N S
Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, Department of Medicine, Division of Cardiology, St. Louis University Medical Center, St. Louis, Missouri, USA.
Invest Ophthalmol Vis Sci. 2000 Dec;41(13):4195-202.
To identify the molecules in normal human intraocular fluid (aqueous humor and vitreous) that inhibit the functional activity of the complement system.
Aqueous humor and vitreous were obtained from patients with noninflammatory ocular disease at the time of surgery. Samples were incubated with normal human serum (NHS), and the mixture assayed for inhibition of the classical and alternative complement pathways using standard CH(50) and AH(50) hemolytic assays, respectively. Both aqueous humor and vitreous were fractionated by microconcentrators and size exclusion column chromatography. The inhibitory molecules were identified by immunoblotting as well as by studying the effect of depletion of membrane cofactor protein (MCP), decay-accelerating factor (DAF), and CD59 on inhibitory activity.
Both aqueous humor and vitreous inhibited the activity of the classical pathway (CH(50)). Microcentrifugation revealed the major inhibitory activity resided in the fraction with an M(r) >/= 3 kDa. Chromatography on an S-100-HR column demonstrated that the most potent inhibition was associated with the high-molecular-weight fractions (>/=19.5 kDa). In contrast to unfractionated aqueous and vitreous, fractions with an M(r) >/= 3 kDa also had an inhibitory effect on the alternative pathway activity (AH(50)). The complement regulatory activity in normal human intraocular fluid was partially blocked by monoclonal antibodies against MCP, DAF, and CD59. Immunoblot analysis confirmed the presence of these three molecules in normal intraocular fluid.
Our results demonstrate that normal human intraocular fluid (aqueous humor and vitreous) contains complement inhibitory factors. Furthermore, the high-molecular-weight factors appear to be the soluble forms of MCP, DAF, and CD59.
鉴定正常人眼内液(房水和玻璃体)中抑制补体系统功能活性的分子。
在手术时从患有非炎性眼病的患者获取房水和玻璃体。将样品与正常人血清(NHS)孵育,然后分别使用标准的CH(50)和AH(50)溶血试验检测混合物对经典和替代补体途径的抑制作用。房水和玻璃体均通过微浓缩器和尺寸排阻柱色谱进行分级分离。通过免疫印迹以及研究膜辅助蛋白(MCP)、衰变加速因子(DAF)和CD59的缺失对抑制活性的影响来鉴定抑制分子。
房水和玻璃体均抑制经典途径(CH(50))的活性。微量离心显示主要抑制活性存在于分子量(M(r))≥3 kDa的组分中。在S - 100 - HR柱上进行色谱分析表明,最强的抑制作用与高分子量组分(≥19.5 kDa)相关。与未分级的房水和玻璃体不同,M(r)≥3 kDa的组分对替代途径活性(AH(50))也有抑制作用。正常人眼内液中的补体调节活性被抗MCP、DAF和CD59的单克隆抗体部分阻断。免疫印迹分析证实了这三种分子在正常眼内液中的存在。
我们的结果表明正常人眼内液(房水和玻璃体)含有补体抑制因子。此外,高分子量因子似乎是MCP、DAF和CD59的可溶性形式。